Cited by 352RNA and protein synthesis mechanismsRNA Interference and Gene DeliveryAdvanced biosensing and bioanalysis techniques

Advancement of the emerging field of RNA nanotechnology

Open access
Jasinski, Daniel, Haque, Farzin, Binzel, Daniel W, Guo, Peixuan·2017·ACS Nano

Abstract

The field of RNA nanotechnology has advanced rapidly during the past decade. A variety of programmable RNA nanoparticles with defined shape, size, and stoichiometry have been developed for diverse applications in nanobiotechnology. The rising popularity of RNA nanoparticles is due to a number of factors: (1) removing the concern of RNA degradation in vitro and in vivo by introducing chemical modification into nucleotides without significant alteration of the RNA property in folding and self-assembly; (2) confirming the concept that RNA displays very high thermodynamic stability and is suitable for in vivo trafficking and other applications; (3) obtaining the knowledge to tune the immunogenic properties of synthetic RNA constructs for in vivo applications; (4) increased understanding of the 4D structure and intermolecular interaction of RNA molecules; (5) developing methods to control shape, size, and stoichiometry of RNA nanoparticles; (6) increasing knowledge of regulation and processing functions of RNA in cells; (7) decreasing cost of RNA production by biological and chemical synthesis; and (8) proving the concept that RNA is a safe and specific therapeutic modality for cancer and other diseases with little or no accumulation in vital organs. Other applications of RNA nanotechnology, such as adapting them to construct 2D, 3D, and 4D structures for use in tissue engineering, biosensing, resistive biomemory, and potential computer logic gate modules, have stimulated the interest of the scientific community. This review aims to outline the current state of the art of RNA nanoparticles as programmable smart complexes and offers perspectives on the promising avenues of research in this fast-growing field.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acsnano.6b05737

Cites

236 of 236 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • DNA and RNA nanotechnologies have been applied to deliver RNA therapeutics such as siRNA and miRNA, mainly for cancer therapy.

    “In addition to viral vectors, DNA and RNA nanotechnologies have also been applied to deliver RNA therapeutics such as siRNA and miRNA, which are mainly used for cancer therapy.[24, 29–33]”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Grodzinski P., Torchilin V., Eds. Advanced Drug Delivery Reviews: Cancer Nanotechnology; Elsevier: Amsterdam, 2014; Vol. 66.

Cited by

Sorted by citations

Authors
Jasinski, D., Haque, F., Binzel, D. W., & Guo, P.
Affiliations
The Ohio State University (US)
Corresponding author
Guo, Peixuan
Venue
ACS Nano
Published
2017-01-03
Volume
11
Issue
2
Pages
1142-1164
ISSN
  • 1936-0851 (ISSN-L)
  • 1936-086X
OpenAlex
W2563634884
Cited by
352
References
236
Citations by year
2026: 20 · 2025: 30 · 2024: 28 · 2023: 40 · 2022: 43 · 2021: 54 · 2020: 49 · 2019: 36 · 2018: 35 · 2017: 17
FWCI
3.51
Type
journal article
Language
en
Open access
Locations
  • ACS Nano (publishedVersion, other-oa)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Cancer Institute (U01CA151648, U01CA207946)
  • National Institute of Biomedical Imaging and Bioengineering (R01EB019036)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced biosensing and bioanalysis techniques
Keywords
RNA nanotechnology, RNA nanoparticles, RNA self-assembly, RNA therapeutics, tissue engineering, biosensing, logic gates, nanobiotechnology
MeSH terms
Animals, Neoplasms, RNA, Thermodynamics, Nanotechnology, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review